Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jun;72(3):210-213.
doi: 10.5455/medarh.2018.72.210-213.

Comparison of Platelet Distribution Width and CA19-9 in Resectable Pancreas Cancer

Affiliations
Free PMC article
Comparative Study

Comparison of Platelet Distribution Width and CA19-9 in Resectable Pancreas Cancer

Kemal Turker Ulutas et al. Med Arch. .
Free PMC article

Abstract

Background: Platelets are considered an important source of prothrombotic agents associated with inflammation in cancer related diseases. We aimed to compare the diagnostic accuracy of the platelet distribution width (PDW) and CA19-9 in resectable pancreas cancer.

Method: A total of 83 stage-1 and 2 pancreatic adenocarcinoma (PAC) patients, and 85 age and sex-matched healthy participants were included in the study. All preoperative patient data, including PDW and CA19-9 were analyzed in terms of sensitivity, specificity, positive and negative predictive values, likelihood ratios, and diagnostic accuracy.

Results: Demographic features were not significantly different among the groups. Platelet distribution width and CA19-9 were significantly higher in PAC compared to control group (p= 0.0001). Diagnostically, the sensitivity and specificity were 79% and 85% for PDW, while 78% and 91% for CA19-9. Diagnostic accuracy was measured by the area under the ROC curve, and PDW differs significantly (p<0.001), with a value of 0.874 (95% CI: 0.804-0.929).

Conclusion: Platelet distribution width indicated similar sensitivity and specificity with CA19-9 in patients with resectable PAC. This result strongly advice that PDW, which has more routine option and cost-effectivity than CA19-9, can be used for diagnosis of resectable PAC as a strong alternative.

Keywords: CA19-9; platelet distribution width; resectable pancreas cancer.

Figures

Figure 1.
Figure 1.. Receiver operating characteristic curves (ROC)

Similar articles

See all similar articles

Cited by 1 article

References

    1. Afsar CU, Gunaldi M, Kum P, Sahin B, Erkisi M, Kara IO, et al. Pancreatic carcinoma, thrombosis and mean platelet volume: single center experience from the southeast region of Turkey. Asian Pacific Journal of Cancer Prevention. 2014;15(21):9143–9146. - PubMed
    1. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Annals of surgical oncology. 2012;19(9):2917–2923. - PubMed
    1. Song X, Zhu H, Pei Q, Tan F, Li C, Zhou Z, et al. Significance of inflammation-based indices in the prognosis of patients with non-metastatic colorectal cancer. Oncotarget. 2017;8(28):45178–45189. - PMC - PubMed
    1. Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. International Journal of Molecular Sciences. 2017;18(3) - PMC - PubMed
    1. Distler M, Pilarsky E, Kersting S, Grutzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. International journal of surgery (London, England) 2013;11(10):1067–1072. - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback